Encouragingly, the phase II (ARC-10) trial reported that domvanilimab combined with the anti-PD-1 mAb zimberelimab improved PFS and OS compared to zimberelimab monotherapy or chemotherapy in PD-L1-high advanced NSCLC [61]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.